Odyssey Group Stock Price, News & Analysis

Odyssey Group International (OTC Pink: ODYY) has established a Military Advisory Board to enhance its focus on treating traumatic brain injuries (TBI) with its drug candidate, PRV-002, currently in Phase 1 clinical trials. The board includes notable military leaders such as Major General Jim Linder and Commanding General Francis Beaudette, who bring extensive experience in addressing TBIs, especially in the military context. Odyssey aims to develop an intranasal device to deliver PRV-002 for immediate treatment post-concussion, addressing a significant medical need.

Odyssey Health, Inc. (OTC Pink: ODYY) is advancing its clinical trial of PRV-002, a novel neurosteroid aimed at treating concussions. Conducted by Nucleus Network in Melbourne, the trial is significant as it seeks to address a critical gap in concussion treatment. NFL Hall of Famer Brett Favre is involved as a sports advisory board member, although he is not a participant in the trial. The medication, delivered nasally, aims to reduce brain swelling and improve recovery outcomes, with a target population that includes sports players and others at risk of brain injuries.

Odyssey Group International, Inc. (OTC Pink: ODYY) announced a $500,000 donation from Erase PTSD Now and the Glenn Greenberg and Linda Vester Foundation to support Phase 1 human clinical trials of PRV-002, a drug aimed at treating concussion. CEO Michael Redmond emphasized the significance of this funding in progressing the trials. The partnership aims to collect data on PTSD and concussion links to enhance treatment for military veterans. PRV-002 is designed to alleviate concussion symptoms and reduce brain inflammation, with the goal of improving recovery outcomes for soldiers.

Odyssey Group International, Inc. (OTC: ODYY) has filed a provisional patent for a novel nasal drug delivery device intended for treating concussions. This device uses a dual wall dispensing system to enhance drug deposition directly into the nasal cavity and olfactory region, aiming to improve treatment outcomes for traumatic brain injuries. CEO Michael Redmond emphasized the device’s potential to deliver PRV-002, a neuroprotective synthetic neurosteroid, rapidly to the brain while minimizing side effects. The company targets further development of neurological drugs utilizing this technology.

Odyssey Group International (OTC: ODYY) announced the successful initiation of its Phase 1 clinical trial for PRV-002, a nasal neurosteroid aimed at treating concussion. Enrollment and screening of subjects have commenced, with the first cohort scheduled for dosing shortly. The trial will evaluate pharmacokinetics and tolerability across three dosage levels. The unique delivery method and the pressing need for concussion treatments are expected to facilitate participant enrollment and compliance. This update indicates significant progress in Odyssey's drug development pipeline.

Odyssey Group International, Inc. (OTC: ODYY) announced its participation in the HC Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The company will present at 7:00 am EDT on September 13. Interested investors can register for the virtual conference HERE. Odyssey focuses on medical solutions, particularly its neurosteroid PRV-002 for treating concussions.

Odyssey Group International (OTC: ODYY) has received approval for Phase 1 clinical trials of PRV-002, a drug candidate aimed at treating concussions. The trial, approved by the Alfred Ethics Committee, will assess safety, tolerability, and pharmacokinetics through a randomized, double-blind, placebo-controlled study. PRV-002 has shown promising results in preclinical studies, indicating potential for brain recovery. The trial will be managed by Avance, Inc. and Nucleus Network, both known for their expertise in clinical trials.

Odyssey Group International (OTC: ODYY) has successfully developed a novel drug-device combination product aimed at treating concussions, completing its formulation for human clinical trials. The product, which can be administered as a spray-dried powder via the nasal cavity, targets brain swelling and oxidative stress post-concussion. Certified by Upperton Limited, the product is prepared for Phase 1 trials. Executive VP Jacob VanLandingham emphasized increased drug efficacy with reduced side effects. The company aims to make significant advancements in medical solutions while addressing substantial market opportunities.

Odyssey Group International, Inc. (OTC: ODYY) recently featured on the show 'Banfield' to discuss their concussion treatment, PRV-002. Key figures from the Sports Advisory Board, including NFL legends Brett Favre, Kurt Warner, and Mark Rypien, highlighted the urgent need for effective concussion therapies. PRV-002, a synthetic neurosteroid, demonstrated strong preclinical results by improving neuroprotective effects and reducing brain injury symptoms. Odyssey aims to raise public awareness about concussions and plans to seek FDA approval for PRV-002.